Collateral cleavage of 28s rRNA by RfxCas13d causes death of mice
Y. Li, J. Xu, X. Guo, Z. Li, L. Cao, S. Liu, Y. Guo, G. Wang, Y. Luo, Z. Zhang, X. Wei, Y. Zhao, T. Liu, X. Wang, H. Xia, M. Kuang, Q. Guo, J. Li, L. Chen, Y. Wang, Q. Li, F. Wang, Q. Liu, F. You
Abstract
The CRISPR-Cas13 system is an RNA-guided RNA-targeting system, and has been widely used in transcriptome engineering with potentially important clinical applications. However, it is still controversial whether Cas13 exhibits collateral activity in mammalian cells. Here, we found that knocking down gene expression using RfxCas13d in the adult brain neurons caused death of mice, which was not resulted from the loss of target gene function or off-target effects. Mechanistically, we showed that RfxCas13d exhibited collateral activity in mammalian cells, which is positively correlated with the abundance of target RNA. The collateral activity of RfxCas13d could cleave 28s rRNA into two fragments, leading to translation attenuation and activation of the ZAK-JNK/p38-immediate early gene (IEG) pathway. These results provide new mechanistic insights into the collateral activity of RfxCas13d and warn that the biosafety of CRISPR-Cas13 system needs further evaluation before applying it to clinical treatments.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Target RNA abundance controls the collateral activity of RfxCas13d in human cells and zebrafish embryos
Honglin Chen, Wenxin Hu, … Mohamed Fareh·bioRxiv·Apr 8, 2026
- Low copy CRISPR-Cas13d mitigates collateral RNA cleavage
Sydney K. Hart, Simon Müller, … Neville E. Sanjana·Nature BiotechnologyPeer-reviewed·Feb 11, 2025
- Enhanced RNA-targeting CRISPR-Cas technology in zebrafish
Ismael Moreno-Sánchez, Luis Hernández-Huertas, … Miguel A. Moreno-Mateos·Nature CommunicationsPeer-reviewed·Mar 16, 2025
- CRISPR/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells
Yuxi Ai, Dongming Liang, Jeremy E. Wilusz·Nucleic Acids ResearchPeer-reviewed·Feb 21, 2022
- High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effect
Huawei Tong, Jia Huang, … Hui Yang·Nature BiotechnologyPeer-reviewed·Aug 11, 2022
- Negative autoregulation mitigates collateral RNase activity of repeat-targeting CRISPR-Cas13d in mammalian cells
Chase P. Kelley, Maja C. Haerle, Eric T. Wang·Cell ReportsPeer-reviewed·Aug 1, 2022